Provocative non-canonical roles of p53 and AKT signaling: A role for Thymosin β4 in medulloblastoma

Int Immunopharmacol. 2023 Mar:116:109785. doi: 10.1016/j.intimp.2023.109785. Epub 2023 Jan 29.

Abstract

The PI3K/AKT and p53 pathways are key regulators of cancer cell survival and death, respectively. Contrary to their generally accepted roles, several lines of evidence, including ours in medulloblastoma, the most common childhood brain cancer, highlight non-canonical functions for both proteins and show a complex context-dependent dynamic behavior in determining cell fate. Interestingly, p53-mediated cell survival and AKT-mediated cell death can dominate in certain conditions, and these interchangeable physiological functions may potentially be manipulated for better clinical outcomes. This review article presents studies in which p53 and AKT behave contrary to their well-established functions. We discuss the factors and circumstances that may be involved in mediating these changes and the implications of these unique roles of p53 and AKT in devising therapeutic strategies. Lastly, based on our recent finding of Thymosin beta 4-mediated chemosensitivity via an AKT-p53 interaction in medulloblastoma cells, we also discuss the possible implications of Thymosin beta-4 in enhancing drug sensitivity in this deadly childhood disease.

Keywords: AKT; Cell death; Cell survival; Medulloblastoma; P53; PI3K; Thymosin beta-4.

Publication types

  • Review

MeSH terms

  • Cerebellar Neoplasms* / drug therapy
  • Child
  • Humans
  • Medulloblastoma* / drug therapy
  • Phosphatidylinositol 3-Kinases / metabolism
  • Proto-Oncogene Proteins c-akt / metabolism
  • Thymosin* / genetics
  • Thymosin* / metabolism
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Protein p53 / metabolism

Substances

  • Proto-Oncogene Proteins c-akt
  • thymosin beta(4)
  • Tumor Suppressor Protein p53
  • Phosphatidylinositol 3-Kinases
  • Thymosin